These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28647392)

  • 21. Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.
    Gillooly KM; Pulicicchio C; Pattoli MA; Cheng L; Skala S; Heimrich EM; McIntyre KW; Taylor TL; Kukral DW; Dudhgaonkar S; Nagar J; Banas D; Watterson SH; Tino JA; Fura A; Burke JR
    PLoS One; 2017; 12(7):e0181782. PubMed ID: 28742141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
    Eda H; Santo L; Cirstea DD; Yee AJ; Scullen TA; Nemani N; Mishima Y; Waterman PR; Arastu-Kapur S; Evans E; Singh J; Kirk CJ; Westlin WF; Raje NS
    Leukemia; 2014 Sep; 28(9):1892-901. PubMed ID: 24518207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of osteoclastogenesis by N,N-dimethyl-D-erythro-sphingosine: a sphingosine kinase inhibition-independent action.
    Kim HJ; Lee Y; Chang EJ; Kim HM; Hong SP; Lee ZH; Ryu J; Kim HH
    Mol Pharmacol; 2007 Aug; 72(2):418-28. PubMed ID: 17504945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
    Tai YT; Chang BY; Kong SY; Fulciniti M; Yang G; Calle Y; Hu Y; Lin J; Zhao JJ; Cagnetta A; Cea M; Sellitto MA; Zhong MY; Wang Q; Acharya C; Carrasco DR; Buggy JJ; Elias L; Treon SP; Matsui W; Richardson P; Munshi NC; Anderson KC
    Blood; 2012 Aug; 120(9):1877-87. PubMed ID: 22689860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effects of Bruton's tyrosine kinase on the proliferation and differentiation of osteoclasts].
    Zhang H; Wang LN; Zuo MN; Dong M; Shi DM; Xu HJ; Niu WD
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2019 Aug; 37(4):361-365. PubMed ID: 31512826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia.
    Annageldiyev C; Gowda K; Patel T; Bhattacharya P; Tan SF; Iyer S; Desai D; Dovat S; Feith DJ; Loughran TP; Amin S; Claxton D; Sharma A
    Haematologica; 2020 Mar; 105(3):687-696. PubMed ID: 31123028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific binding of the WASP N-terminal domain to Btk is critical for TLR2 signaling in macrophages.
    Sakuma C; Sato M; Takenouchi T; Kitani H
    Mol Immunol; 2015 Feb; 63(2):328-36. PubMed ID: 25213142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RANKL downregulates cell surface CXCR6 expression through JAK2/STAT3 signaling pathway during osteoclastogenesis.
    Li C; Zhao J; Sun L; Yao Z; Liu R; Huang J; Liu X
    Biochem Biophys Res Commun; 2012 Dec; 429(3-4):156-62. PubMed ID: 23142594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ginsenoside Rb2 inhibits osteoclast differentiation through nuclear factor-kappaB and signal transducer and activator of transcription protein 3 signaling pathway.
    Cong F; Liu J; Wang C; Yuan Z; Bi L; Liang J; Su K; Qiu Y; Song T; Fan J; Chao G
    Biomed Pharmacother; 2017 Aug; 92():927-934. PubMed ID: 28605877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zerumbone abolishes RANKL-induced NF-kappaB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice.
    Sung B; Murakami A; Oyajobi BO; Aggarwal BB
    Cancer Res; 2009 Feb; 69(4):1477-84. PubMed ID: 19190327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Euphorbia factor L1 inhibits osteoclastogenesis by regulating cellular redox status and induces Fas-mediated apoptosis in osteoclast.
    Hong SE; Lee J; Seo DH; In Lee H; Ri Park D; Lee GR; Jo YJ; Kim N; Kwon M; Shon H; Kyoung Seo E; Kim HS; Young Lee S; Jeong W
    Free Radic Biol Med; 2017 Nov; 112():191-199. PubMed ID: 28774817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo.
    Sakai E; Aoki Y; Yoshimatsu M; Nishishita K; Iwatake M; Fukuma Y; Okamoto K; Tanaka T; Tsukuba T
    Phytomedicine; 2016 Jul; 23(8):828-37. PubMed ID: 27288918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
    Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
    BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bortezomib inhibits human osteoclastogenesis.
    von Metzler I; Krebbel H; Hecht M; Manz RA; Fleissner C; Mieth M; Kaiser M; Jakob C; Sterz J; Kleeberg L; Heider U; Sezer O
    Leukemia; 2007 Sep; 21(9):2025-34. PubMed ID: 17581612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
    Ichikawa H; Murakami A; Aggarwal BB
    Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. D-pinitol inhibits RANKL-induced osteoclastogenesis.
    Liu SC; Chuang SM; Tang CH
    Int Immunopharmacol; 2012 Mar; 12(3):494-500. PubMed ID: 22269833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase.
    Buhl AM; Cambier JC
    J Immunol; 1999 Apr; 162(8):4438-46. PubMed ID: 10201980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.